N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
about
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responsesN-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseEltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Glutamate receptor ion channels: structure, regulation, and functionGABA(B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates.Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists.Treatment of early Parkinson's disease.Hemiballism: report of 25 cases.NMDA receptors in the basal ganglia.Neuroprotective potential of ionotropic glutamate receptor antagonists.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesDevelopment of allosteric modulators of GPCRs for treatment of CNS disordersThe involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.Altered neuronal activity relationships between the pedunculopontine nucleus and motor cortex in a rodent model of Parkinson's disease.Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons.Antioxidative therapeutic strategies for Parkinson's disease.The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses.Glutamate receptors as therapeutic targets for Parkinson's disease.The origins of oxidant stress in Parkinson's disease and therapeutic strategies.Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat.Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride.The role of excitatory amino acids in experimental models of Parkinson's disease.Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?--case of amantadine and memantine.Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons.Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications.The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury.Pre-synaptic glutamate-induced activation of DA release in the striatum after partial nigral lesion.Knockdown of the aryl hydrocarbon receptor attenuates excitotoxicity and enhances NMDA-induced BDNF expression in cortical neurons.Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.Tyrosine dephosphorylation and ethanol inhibition of N-Methyl-D-aspartate receptor function.Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease.Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.Antiparkinsonian actions of glutamate antagonists--alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms.Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice.Metabolomic Analysis Provides Insights on Paraquat-Induced Parkinson-Like Symptoms in Drosophila melanogaster.Alterations of NMDA receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats.
P2860
Q21560808-A47581A8-3757-45C1-828B-546A606F601DQ26825619-3BF68E91-C6F5-419A-8269-56A2BCBE3366Q27303857-84A2F13E-F799-4534-8578-5CB3BED9458DQ28290774-1289487E-9E9B-4725-8276-CB4879E8B3CDQ30893059-F089270B-0733-4CC5-806D-CE1113C19D66Q33515060-950745F8-FAF0-4C3C-81FE-C19EEEB084CEQ33714133-F367EF58-74D3-4657-97AB-F7F767DCDCFCQ33732902-7FD9CC2F-EA86-4E2E-8934-C3913C625DCBQ33989361-CAFCA961-088B-4C99-9663-2A0A80A84AA6Q34209297-A62025BE-BFF8-4F46-A57D-1F017A588166Q34329204-C30F2AE7-6026-40DE-803F-A04E13607EABQ34373958-22B359CB-53BA-4A41-985C-9898D1793514Q35029070-B2298834-53C1-4867-8AEB-8394CF020DACQ35053904-403A3822-0224-415B-AE0D-3990EFD322E1Q36169973-9C24E458-65DB-430F-B5C0-0F82BC065838Q36349448-2920F05D-4907-4A80-8B0C-F599D15B93F2Q36833070-87949CBA-D4DD-47CB-AD2B-094F4555B716Q37585401-D10C264E-1FE0-47A2-9C37-3C8FCE1BE1C0Q37780206-A1903D7E-1B05-4C76-B41D-9ED4D3975599Q38308644-9BF4DECC-9CBA-424A-9C43-BF00B7182621Q38447289-66645091-D9DB-429D-8332-A6061C6EE1BAQ40374501-3DC10D0A-554F-4284-9A4E-9EB854E30644Q40398681-D0491A57-F59E-4D8F-B6DF-D2BF5A184B04Q40551337-0ACACCD2-BBA6-403A-A082-BCCA977F581DQ40662075-64A573C5-1C07-4100-99AB-3DD9EBDF3FCBQ42278528-8ABA9EC9-98AE-4122-9092-49994F04FF34Q42450443-FB54D732-468E-43C1-A82B-E8768B0A9F1EQ42637057-256BA8E0-6C6E-4B82-BB06-CA9B30C65CFBQ42749859-C599B5B1-01F7-453A-808C-E5C2C7D97882Q43117401-6211208E-5BFC-40EB-8C5A-FAC4A95BCAD5Q43284920-A8579B4E-4F91-4B30-B4AA-8ED09222451DQ44165271-2939466A-0211-4770-A426-FE6806692C24Q44283752-A58ECDE9-5F3D-4B3B-A259-EC892005D84FQ45252695-1287DB2C-C64E-4DD9-8970-8DBD6BCAD190Q45985296-0FB466ED-3578-4A97-A3AF-30B7145FC41CQ46428813-4011E740-B935-438F-BFA5-D155D0C551BBQ47994663-4504D1B6-B0B1-4CEF-B7A2-FB4C7CABD93BQ48152487-E78B4355-01FF-4593-B65D-57CA9C62688EQ48445931-9870A02C-3C29-4C12-A54D-FF3222B3A716Q48952241-33A4C526-DEB9-4557-B620-9337B566EDE3
P2860
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
@en
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
@nl
type
label
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
@en
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
@nl
prefLabel
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
@en
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
@nl
P1433
P1476
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
@en
P2093
Greenamyre JT
O'Brien CF
P304
P356
10.1001/ARCHNEUR.1991.00530210109030
P577
1991-09-01T00:00:00Z